A partnership was created through a Sponsored Research Agreement SRAA) funded by MTF that defined the development activity protocols, resources, and safety and efficacy outcomes required to translate the technology to commercialization.
To translate the technology to clinical applications, we aimed to demonstrate massive bone healing in minipigs that more closely mimicked the clinical scenarios, using a new hybrid baculovirus system consisting of BacFLPo expressing the codon-optimized FLP recombinase (FLPo) and the substrate baculovirus harboring the transgene flanked by Frt sequences.
However, to translate the iPSC technology to therapy quickly, extensive preclinical experiments are required to evaluate the safety and effectiveness of this new type of therapy.
The challenge in translating this technology to humans, where the tumor will be much smaller relative to the entire bladder at the time of imaging, will be improving the specificity for TCC to obtain the strongest signal possible.
However, the difficulties of translating this technology into a viable therapeutic option in the clinic should not be underestimated.
Their future outlook in regenerative medicine including the current clinical significance of NDs, as well as the challenges that must be overcome to successfully translate the reviewed technologies from research platforms to clinical therapies will also be discussed.
Therefore translating the findings from this new technology into vaccines and treatment will require the consideration of the phenotypic effects of these genes on the iRBC, not just in isolation, but in the context of human infection and disease.
But more important, we need to translate these biomarkers from discovery to clinical diagnostics using good strategies, such as the lessons learned from translating the biomarkers discovered using proteomic technologies to OVA 1, the first FDA-cleared In Vitro Diagnostic Multivariate Index Assay (IVDMIA).
However, there are still challenges presented by the degenerating recipient retinal environment that must be addressed as we move to translating these technologies towards clinical application.
A major objective of clinical genomics is to translate the knowledge and technologies that are established in a discovery setting, for example, large-scale cancer genome sequencing, into a clinical setting to benefit individual patients [ 1].
